Metabolic Psychiatry: What The Evidence Actually Shows

Metabolic psychiatry is the idea that mental illness is, for some people, partly a problem of how the body and brain make and use energy. The machinery that keeps a cell powered: insulin, inflammation, mitochondria, blood sugar. When that machinery struggles, the mind can struggle with it.

One concrete example is the link between weight loss and depression.

I came to it sideways. I started paying attention to GLP-1 medications because my patients were already on them, and I kept noticing mood and craving changes nobody had warned them about. That curiosity pulled me into a literature I now think every psychiatrist should know. This is my honest read of it: what the evidence supports, what the internet has inflated, and where I think the field is actually going.

The metabolism-and-addiction overlap shows up in the emerging link between GLP-1 medications and alcohol.

The same metabolic-first thinking shapes how I run an ADHD evaluation in adults: thyroid, iron, and blood sugar get checked before the problem gets pinned on dopamine alone.

For a head-to-head on the drugs themselves, see semaglutide vs tirzepatide vs retatrutide.

What Metabolic Psychiatry Actually Means

The term was coined around 2015 by Dr. Shebani Sethi at Stanford, after she noticed how many of her treatment-resistant psychiatric patients also had insulin resistance, prediabetes, or obesity. The premise is simple. If metabolic dysfunction and mental illness keep showing up together, maybe treating the metabolism changes the mind.

That premise has real evidence behind it now. It also has a fast-growing fan base online, a lot of supplement sellers, and a few genuinely contradictory camps that all use the same words to mean different things. Sorting the signal from the noise is most of the work.

The Metabolic Case For Depression

Start with the strongest finding. A 2021 Dutch cohort study followed 601 adults who had never had depression or anxiety. People who were insulin resistant at baseline had roughly double the risk of developing major depression over the next nine years (PMID 34551583). The metabolic problem came first. The depression came later.

That fits a larger pattern. A meta-analysis of longitudinal studies found that obesity and depression each raise the risk of the other, a two-way street (PMID 20194822). And inflammation, which tends to travel with metabolic dysfunction, is now a well-described driver in a subset of depression (PMID 26711676).

None of this says metabolism explains all depression. It says metabolism is one real lever, often missed, in a condition we used to explain almost entirely with the serotonin story that the literature has largely abandoned. For some patients, the better question isn’t which antidepressant. It’s whether anyone checked the fasting insulin.

How GLP-1 Medications Pulled Me In

I’m a psychiatrist, not an obesity doctor. I got interested in this because of who was sitting in front of me. Over the last two years, a growing share of my patients arrived already taking semaglutide or tirzepatide, prescribed elsewhere for weight or diabetes, and some of them described real shifts in mood, anxiety, or the urge to drink.

The research is early and mostly observational, so I hold it loosely. A large cohort study of diabetic patients found lower rates of anxiety and depression among GLP-1 users than matched non-users, with the anxiety signal stronger and most pronounced in women (PMID 35281896). That’s an association in people with diabetes, not proof these drugs treat mood. But it lines up with what I was seeing, and it’s why I started reading instead of dismissing it.

If you want the deeper dive on how these drugs act on the brain’s reward and mood circuitry, I wrote a full piece on GLP-1 medications and mental health, and a separate one on whether a psychiatrist can prescribe weight-loss medication at all.

When a GLP-1 is the right tool and someone wants it managed start to finish, that runs through the practice’s medical weight loss program for North Carolina, where labs, dosing, and mood are followed on one plan.

The Ketogenic Diet Craze, And What It Gets Right

Say “metabolic psychiatry” to most people who follow it online and they’ll picture a ketogenic diet. That’s the loudest part of the field, and the part most prone to overpromising. So let me be careful here, because the honest position is in the middle.

The serious evidence is real but early. A 2024 Stanford pilot put 23 adults with bipolar disorder or schizophrenia, all with existing metabolic problems, on a ketogenic diet for four months. Insulin resistance dropped about 27 percent, and psychiatric symptoms improved meaningfully, with most participants showing clinically significant gains (PMID 38547601). That’s a striking result in a hard-to-treat group.

It’s also a single-arm pilot of 23 motivated people with no control group. It’s promising. It hasn’t been proven. The diet is demanding, it interacts with several psychiatric medications, and it isn’t something to start on your own. When someone tells you keto cures mental illness, they’ve run past the data. When someone tells you food has nothing to do with the brain, they’ve ignored it.

If you’re weighing a metabolic approach for your own care, that’s a conversation to have with a clinician who knows your history. You can book a consultation to talk it through rather than piecing it together from social media.

Where Ray Peat Fits, And Where The Evidence Parts Ways

You can’t write honestly about this movement without mentioning Ray Peat. Peat was a biologist whose “bioenergetic” writing built a large and devoted online following, and a lot of today’s metabolic-mental-health enthusiasm traces back to ideas he popularized: that health flows downstream of cellular energy, that thyroid function and metabolic rate shape mood, that chronic stress and the wrong fuels grind the system down.

Here’s the part his followers and the keto camp both tend to miss: Peat was against ketogenic diets. He argued the body runs best on adequate carbohydrate and saw ketosis as a stress state. So the single banner of “metabolic psychiatry” actually shelters two camps that prescribe nearly opposite things, and the public conversation rarely admits it.

I take the durable insight seriously. Energy metabolism matters to the brain, and mainstream psychiatry was slow to say so. But I treat Peat the way I’d treat any thinker outside the trial literature: his framework is a hypothesis generator, not a protocol. Much of what gets attributed to him, the specific claims about sugar, thyroid, and seed oils fixing mental illness, hasn’t been tested in controlled trials. Where the data exist, I follow them. Where they don’t, I say so plainly rather than fill the gap with confidence.

Metabolic Medications: Metformin and the GLP-1s

The medication side of metabolic psychiatry gets less attention than diet, and I think that’s backwards, because the trials are often cleaner.

Take metformin. A randomized trial in treatment-resistant bipolar depression gave patients with insulin resistance either metformin or placebo. The patients who actually reversed their insulin resistance, almost all of them on metformin, had significant improvements in depression and functioning, with large effect sizes (PMID 35120288). The trial was small and the key comparison was between responders and non-responders, so I read it as a promising lead that needs replication, not a finished answer. But it points somewhere real.

The GLP-1 data sit in the same category: encouraging signals, mostly from observational work, that justify attention and monitoring rather than sweeping claims. The throughline is that fixing the metabolic problem sometimes moves the psychiatric one. That’s the hypothesis worth testing carefully, and the one I keep watching.

Metabolism and the Urge to Drink: An Early Signal Worth Knowing

One of the most interesting threads, and one I’m following closely for educational reasons rather than offering as a service, is what these drugs do to craving.

In a 2025 phase 2 randomized trial, 48 adults with alcohol use disorder received low-dose semaglutide or placebo for nine weeks. The semaglutide group drank less in a controlled lab setting and reported less weekly craving, with a hint of reduced smoking in a subgroup (PMID 39937469). It’s a small, short, early trial. It is not a green light to use these drugs for addiction.

But it matters, because it suggests the same reward circuitry that governs appetite also touches the desire to drink. As the science matures, I expect metabolic tools to become part of how we think about substance use. For now I’m telling patients what the evidence shows and what it doesn’t, which is the responsible version of staying current.

What This Means For Your Care, and What it Doesn’t

I don’t run a “metabolic psychiatry clinic,” and I’d be wary of anyone marketing a one-size protocol under that name. What I do is treat metabolism as part of a full psychiatric evaluation, because the evidence says it belongs there.

In practice that means asking about weight history and energy, looking at metabolic labs when the picture warrants it, and noticing when a depression that hasn’t responded to standard treatment sits alongside untreated insulin resistance. It means coordinating with the prescriber when a patient is on a GLP-1, the way I’d coordinate around any medication that acts on the brain. It connects to work I already do across depression care in North Carolina and the overlap between hormones and mood, because the body doesn’t silo these problems the way clinics do.

Metabolic psychiatry won’t replace antidepressants, therapy, or good diagnosis. The strong version of the hype will disappoint people. But the modest, evidence-bound version is one of the more useful shifts in the field, and it deserves a place in the conversation about your treatment.

Frequently Asked Questions

Is metabolic psychiatry an established medical specialty?

No. It’s an emerging area of research and clinical interest, not a board-certified specialty. The term describes a focus on the link between metabolic health and mental illness. Treat anyone presenting it as a packaged, guaranteed cure with caution.

Can changing my diet treat my depression?

For some people, metabolic factors contribute to depression, and addressing them may help. But the trial evidence is strongest in serious mental illness and still early, and diet is not a substitute for proper diagnosis and treatment. Any major dietary change for a psychiatric condition should be done with a clinician, especially if you take medication.

Do GLP-1 medications like Ozempic help with mood?

Observational studies show lower rates of anxiety and depression among some GLP-1 users, and in January 2026 the FDA asked manufacturers to remove the suicidality warning after a large review found no increased risk. That’s reassuring, but these drugs aren’t approved to treat mood, and a subset of people do report psychiatric changes, so monitoring matters.

Where does Ray Peat fit into all this?

Peat’s bioenergetic ideas helped popularize the view that metabolism shapes mental health, and that core insight has merit. But many of his specific claims haven’t been tested in controlled trials, and his anti-ketogenic, pro-carbohydrate stance actually contradicts the keto-focused wing of metabolic psychiatry. I find his thinking useful as a prompt, not as a protocol.

Do you offer metabolic psychiatry in North Carolina?

I incorporate metabolic factors into a full psychiatric evaluation when they’re relevant, rather than offering a separate “metabolic” program. My practice is cash-pay telehealth for adults across North Carolina. If you want to understand how metabolism might relate to your symptoms, that’s a reasonable thing to bring to a consultation.

This article is for educational purposes only and is not medical advice. It does not create a physician-patient relationship. Medications, including GLP-1 receptor agonists and metformin, and significant dietary changes should be undertaken only under the supervision of a qualified clinician who knows your history. If you are in crisis, call or text 988.

References

1. Watson KT, Simard JF, Henderson VW, et al. Incident Major Depressive Disorder Predicted by Three Measures of Insulin Resistance: A Dutch Cohort Study. Am J Psychiatry. 2021;178(10):914-920. PMID 34551583.
2. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-229. PMID 20194822.
3. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34. PMID 26711676.
4. Tsai WH, Sung FC, Chiu LT, et al. Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study. Front Pharmacol. 2022;13:765446. PMID 35281896.
5. Calkin CV, Chengappa KNR, Cairns K, et al. Treating Insulin Resistance With Metformin as a Strategy to Improve Clinical Outcomes in Treatment-Resistant Bipolar Depression (TRIO-BD). J Clin Psychiatry. 2022;83(2):21m14022. PMID 35120288.
6. Sethi S, Wakeham D, Ketter T, et al. Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial. Psychiatry Res. 2024;335:115866. PMID 38547601.
7. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. PMID 39937469.
8. U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications. Drug Safety Communication, January 13, 2026. FDA.gov.